Biotech · Private company
Vascular Biogenics Ltd. operating as VBL Therapeutics
Track this companyFree. Adds Vascular Biogenics Ltd. operating as VBL Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- VB-111 + PaclitaxelPhase 3 · Recurrent Platinum Resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Glioblastoma MultiformeClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Platinum Resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- VB-111Phase 2 · Glioblastoma MultiformeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- VB-111 in Surgically Accessible Recurrent/Progressive GBMPHASE2 · TERMINATED · started Aug 1, 2020ClinicalTrials.gov NCT04406272 · fetched Nov 12, 2026
- A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)PHASE3 · COMPLETED · started Dec 19, 2017ClinicalTrials.gov NCT03398655 · fetched Nov 12, 2026
- A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian CancerPHASE1_PHASE2 · COMPLETED · started Nov 1, 2012ClinicalTrials.gov NCT01711970 · fetched Nov 12, 2026
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma MultiformePHASE1_PHASE2 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01260506 · fetched Nov 12, 2026